What changed today in Metabolic: 4 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Obesity drug pipeline
Investigational obesity and metabolic medicines in clinical development — multi-agonists, amylin combinations, muscle-preserving agents and oral therapies.
High attention
- Editorial attention
- High attention
- Tracked this week
- 13
- Sources this week
- 6
- Last activity
- 2 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Obesity drug pipeline at a glance
- About this topic
- Investigational obesity and metabolic medicines in clinical development — multi-agonists, amylin combinations, muscle-preserving agents and oral therapies.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 12, 2026)
- Key facts from tracked records
- 189 clinical trials tracked from ClinicalTrials.gov
- 12 NPHLA briefings on this topic
What’s the latest on Obesity drug pipeline?
12 totalWhat changed today in Metabolic: 5 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
What changed today in Metabolic: 4 new studies, 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
What changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What changed today in Metabolic: 8 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
What changed today in Metabolic: 4 trial updates, 4 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet (opens the source in a new tab)
Phase 1, Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Food Effect in Healthy Volunteers; Weight Management. Interventions: Dose 1; Dose 2. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity (opens the source in a new tab)
Phase 2, Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Overweight , Obesity; Weight Management. Interventions: ecnoglutide tablet; placebo with matching dosage. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes (opens the source in a new tab)
Not applicable, Peking University People's Hospital. Conditions: Type 1 Diabetes. Interventions: Mazdutide; Placbo. Investigational: trial-stage therapies are not approved for the use studied.
- Rethinking endpoints for anti-obesity pharmacotherapy in patients with hr+ early breast cancer receiving endocrine therapy: from body weight and BMI to body composition (opens the source in a new tab)
- Trial status changed to “Recruiting”: MARITIME-T2D-3 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Amgen. Previously “Not yet recruiting”. Conditions: Diabetes Mellitus, Type 2. Interventions: Maridebart cafraglutide; Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After… (opens the source in a new tab)
Phase 1, Amgen. Conditions: Obesity; Overweight. Interventions: Maridebart cafraglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Differentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity (opens the source in a new tab)
- GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment (opens the source in a new tab)
Which clinical trials are being tracked?
All trials- A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet
Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Food Effect in Healthy Volunteers; Weight Management. Investigational — not approved for the use studied.
- Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight
Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Investigational — not approved for the use studied.
- SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Hudson Biotech. Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Investigational — not approved for the use studied.
- A Retrospective Study to Assess Patient-Reported Treatment Experience With Over-the-Counter Analgesic Products
HALEON. Conditions: Pain. Investigational — not approved for the use studied.
- PRESERVE GLP-1: Lifestyle Strategies to Preserve Muscle and Reduce Cardiovascular Risk in Adults With Obesity Using GLP-1 Receptor Agonists
University of Florida. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- Changes in Body Composition and Muscle Composition After GLP-1 Receptor Agonist Therapy in Patients With Obesity
Ulsan University Hospital. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity (opens the source in a new tab)
- Beyond Weight Loss: Survodutide's Cardiometabolic Effects (opens the source in a new tab)
- AHA 2026: Pharmacists at the Center of Cardiometabolic Care (opens the source in a new tab)
- Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint (opens the source in a new tab)
- SYNCHRONIZE-CVOT: Testing a New Incretin Class for CV Safety (opens the source in a new tab)
- Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT (opens the source in a new tab)